Compassionate access to new hepatitis C drugs an "emergency" for European patients
Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80%
Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C
Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis
Hep C quad regimens quashed, but some components go forward
Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care
A majority of HIV-positive gay men in Dutch survey take their viral load into consideration if having unprotected sex
Researchers stop the only current HIV vaccine efficacy trial
AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1
